Balasa Dinverno & Foltz LLC Dexcom Inc Transaction History

Balasa Dinverno & Foltz LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$67.99 - $132.89 $144,274 - $281,992	2,122 Added 239.5%	3,008 $224,000
Q1 2022 Apr 25, 2022	SELL	$94.08 - $130.2 $6,867 - $9,504	-73 Reduced 7.61%	886 $453,000
Q4 2021 Jan 26, 2022	BUY	$129.87 - $162.82 $259 - $325	2 Added 0.21%	959 $515,000
Q3 2021 Oct 26, 2021	SELL	$106.71 - $143.18 $3,414 - $4,581	-32 Reduced 3.24%	957 $523,000
Q2 2021 Jul 23, 2021	SELL	$80.99 - $107.93 $9,475 - $12,627	-117 Reduced 10.58%	989 $422,000
Q1 2021 Apr 29, 2021	SELL	$84.79 - $104.74 $5,087 - $6,284	-60 Reduced 5.15%	1,106 $397,000
Q4 2020 Jan 26, 2021	SELL	$78.0 - $104.5 $16,458 - $22,049	-211 Reduced 15.32%	1,166 $431,000
Q3 2020 Nov 10, 2020	SELL	$95.51 - $112.95 $45,367 - $53,651	-475 Reduced 25.65%	1,377 $568,000
Q2 2020 Aug 07, 2020	BUY	$62.68 - $105.34 $52,463 - $88,169	837 Added 82.46%	1,852 $751,000
Q1 2020 Apr 30, 2020	BUY	$47.79 - $75.63 $48,506 - $76,764	1,015 New	1,015 $273,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Balasa Dinverno & Foltz LLC, based on Form 13F filings with the SEC.

Stay updated on Balasa Dinverno & Foltz LLC with notifications on news.